Generex Biotechnology Corporation Announces Publication of Novel Immunotherapeutic Cancer Vaccine Studies

WORCESTER, Mass., Jan. 12, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today the publication of a report reviewing the studies performed to date with the immunotherapeutic agent AE37, which is being developed by the Company's wholly-owned immunotherapeutics subsidiary Antigen Express, Inc. (www.antigenexpress.com). The compound is currently the subject of a Phase II clinical trial in patients with breast cancer, a Phase I clinical trial in prostate cancer patients, and another Phase I clinical trial wherein the compound will be combined with another vaccine peptide in patients with either ovarian or breast cancer.

Back to news